Kelowna, British Columbia – May 16, 2025 – TheNewswire – Rize Oncology Inc. (CSE: RIZE) (“Rize Oncology” or the “Company”), a clinical-stage pharmaceutical company focused on developing innovative oncology therapeutics, today announced several strategic developments to support the ongoing advancement of its drug candidate, STS-201.

The Company has received the approval of a simple majority of its disinterested shareholders, as well as the approval of the of the Canadian Securities Exchange (“CSE”), to voluntarily delist its common shares from the CSE.  It is expected that the delisting will become effective at the close of trading on May 23, 2025. Notwithstanding the delisting, Rize Oncology will continue to be a reporting issuer in each of the provinces of British Columbia, Alberta and Ontario and will continue to make all required public filings on the System for Electronic Document Analysis and Retrieval (SEDAR+) in accordance with applicable Canadian securities laws.

“We believe the current market conditions and trading activity on the CSE do not reflect the underlying value or long-term potential of STS-201 or Rize Oncology as a whole,” said Daren Graham, Executive Chairperson of Rize Oncology. “With this transition, we believe we will have greater flexibility to execute our clinical development strategy.”

Advancing STS-201 and Expanding Globally

As part of its operational strategy, Rize Oncology recently established a wholly-owned subsidiary in Australia. In addition to serving as a regional hub for R&D and clinical activities, the establishment of Rize Oncology Australia Pty Ltd will position the Company to access Australia’s 43.5% R&D rebate program and related grant opportunities.

“Establishing a presence in Australia reflects our commitment to building the company in a capital-efficient and strategically focused way,” stated William Garner, MD, co-founder and director of Rize Oncology. “Rize is just the latest EGB Ventures portfolio company to expand into the region. In addition to EGB’s large and growing network of professionals and investors in the country, we intend to take full advantage Australia’s supportive regulatory environment, world-class clinical infrastructure, and meaningful financial incentives for R&D-stage pharma companies.”

CDMO Agreement with PharmSky Research

Rize Oncology has also entered into a manufacturing agreement with PharmSky Research Pty Ltd, a Melbourne-based contract development and manufacturing organization (CDMO) and initiated manufacturing of the drug product and clinical trial materials required for the Company’s first clinical trial of STS-201, a novel small-molecule therapy in development for soft tissue sarcoma (STS). Based on the significant amount of clinical data available for the active molecule in STS-201, Rize Oncology believes STS-201 holds significant potential as an anti-metastatic compound and as a neoadjuvant to radiation therapy in STS and other solid tumors.

Looking Ahead

“These steps mark a significant inflection point for the company,” said Mr. Graham. “We are laser-focused on bringing STS-201 into the clinic, and these operational enhancements align our structure with that goal.”

About Rize Oncology Inc.

Rize Oncology Inc. is a clinical-stage biopharmaceutical company dedicated to the development of STS-201, a small-molecule drug with a unique mechanism of action, currently being evaluated for its potential in treating soft tissue sarcoma and other cancers.​

Contact:

Roland Boivin, CEO

(833) 294-4363 ext. 1

roland@rizeoncology.com

 

Daren Graham, Executive Chairman

(833) 294-4363 ext. 2

daren@rizeoncology.com

Forward-Looking Statements

This news release contains statements that constitute “forward-looking statements.” Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause Rize Oncology’s actual results, performance or achievements, or developments in the industry to differ materially from the anticipated results, performance or achievements expressed or implied by such forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words “expects,” “plans,” “anticipates,” “believes,” “intends,” “estimates,” “projects,” “potential” and similar expressions, or that events or conditions “will,” “would,” “may,” “could” or “should” occur. Forward-looking statements in this document include the Company’s expectation that its common shares will be delisted from the CSE and the effective date thereof, the expectation that the delisting will provide greater flexibility for Rize Oncology to execute on its clinical development strategy, its expectation that STS-201 holds significant potential as an anti-metastatic compound and as a neoadjuvant to radiation therapy in STS and other solid tumors, and all other statements that are not statements of historical fact.

Although Rize Oncology believes the forward-looking information contained in this news release is reasonable based on information available on the date hereof, by their nature forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements, or other future events, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements.  By their nature, these statements involve a variety of assumptions, known and unknown risks and uncertainties and other factors, which may cause actual results, levels of activity and achievements to differ materially from those expressed or implied by such statements.

Examples of such assumptions, risks and uncertainties include, without limitation, assumptions, risks and uncertainties associated with general economic conditions; adverse industry events; future legislative and regulatory developments; the Company’s ability to access sufficient capital from internal and external sources, and/or inability to access sufficient capital on favorable terms; the ability of Rize Oncology to implement its business strategies; competition; the ability of Rize to obtain and retain all applicable regulatory and other approvals and other assumptions, risks and uncertainties that may be disclosed in the Company’s continuous disclosure record from time to time.